About Gaby Hobbs, MD
I am a hematology-oncology physician who specializes in the care of patients with myeloproliferative neoplasms (MPN), chronic myeloid leukemia and leukemia. I am an active clinical researcher and lead the MPN research program at MGH; I lead several clinical trials and participate in translational research for MPN. In addition, I am the clinical director for the adult leukemia service at MGH.
In addition, I strive to provide compassionate care for each patient and his or her family and to tailor therapy to meet each patient's individual needs.
I grew up in Mexico city and I am fluent in Spanish. I welcome taking care of patients that speak primarily Spanish.
Clinical Interests:
- Essential thrombocytosis
- Leukemia
- Myelofibrosis
- Myeloproliferative neoplasms
- Polycythemia vera
Treats:
- Adult
Languages:
- Spanish
Locations
Mass General Cancer Center
55 Fruit St.
Boston, MA 02114
Phone: 877-726-5130
Mass General Cancer Center in Waltham
52 Second Ave.
Suite 1110
Waltham, MA 02451
Phone: 781-487-6100
Medical Education
- MD, Mount Sinai School of Medicine
- Residency, Brigham and Women's Hospital
- Fellowship, Memorial Sloan Kettering Cancer Center
American Board Certifications
- Hematology, American Board of Internal Medicine
- Internal Medicine, American Board of Internal Medicine
- Medical Oncology, American Board of Internal Medicine
Accepted Insurance Plans
- Aetna
- Beech Street
- Blue Cross Blue Shield
- Blue Cross Blue Shield Medicare
- Cigna
- Commonwealth Care Alliance
- Coventry
- Fallon Health
- Harvard Pilgrim Health Care
- Humana
- Maine Community Health Options
- Mass General Brigham Health Plan
- MassHealth
- Medicaid CT
- Medicaid ME
- Medicaid NH
- Medicaid RI
- Medicaid VT
- Medicare
- Medicare ACO
- Multiplan
- Senior Whole Health
- TriCare
- Tufts Health Plan
- United Health Care
- Wellpoint
- WellSense
- WellSense NH
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Publications
-
Select Publications:
- Hobbs GS, Hanasoge Somasundara AV, Kleppe M, Litvin R, Arcila M, Ahn J, Mckenney AS, Knapp K, Ptashkin R, Weinstein H, Heinemann MH, Francis J, Chanel S, Berman E, Mauro M, Tallman MS, Heaney ML, Levine RL, Rampal RK. Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with MPNs. Haematologica. 2017 Oct 19.
- Hobbs GS, Rozelle S, Mullally A. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. Hematol Oncol Clin North Am. 2017 Aug;31(4):613-626. doi: 10.1016/j.hoc.2017.04.002. Epub 2017 May 17. Review.
- Hobbs GS, Rampal RK. Clinical and molecular genetic characterization of myelofibrosis. Curr Opin Hematol. 2015 Mar;22(2):177-83.
- Hobbs, G*., Hamdi*, A., Hilden, P., Goldberg, J, Poon, M., Ledesma, M., Devlin, S., Rondon, G.. Papadopoulos, E., Jakubowski, A., O'Reilly, R., Champlin, R., Giralt, S., Perales, M*, Kebriaei, P*. Outcomes in Patients with Acute Lymphoblastic Leukemia in First or Second Complete Remission Receiving Ex-Vivo T-Cell Depleted or Unmodified Allografts: Comparison of Results at Two Institutions. Bone Marrow Transplant, January, 26, 2015.
- Hobbs, G.S., Landrum, M.B., Arora, N.K., Ganz, P.A., van Ryn, M., Weeks, J.C., Mack, J.M., Keating, N.L. The Role of Families in Decisions Regarding Cancer Treatments. Cancer, in press.